The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts

Anti-Cancer Drugs

Volumn 24, Issue 6, 2013, Pages 599-608

  Deberne, Mélanie ^a,b   Levy, Antonin ^a,b   Mondini, Michele ^a   Dessen, Philippe ^b   Vivet, Sonia ^a   Supiramaniam, Ajitha ^a   Vozenin, Marie Catherine ^a   Deutsch, Eric ^a,b  

^a Institut Gustave Roussy   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

cervical cancer; cetuximab; cidofovir; epidermal growth factor receptor; human papillomavirus; oncoprotein

Indexed keywords

CETUXIMAB; CIDOFOVIR; HISTONE H2AX; TRANSCRIPTION FACTOR EGR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; S PHASE CELL CYCLE CHECKPOINT; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; WART VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL CYCLE; CELL LINE, TUMOR; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; ORGANOPHOSPHONATES; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 84878939724     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283612a71     Document Type: Article

References (43)

1. Wallboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19. (Pubitemid 29406813)
2. Zur Hausen H, de Villiers EM. Human papillomavirus. Annu Rev Microbiol 1994; 48:427-447.
3. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 1995; 9:2335-2349.
4. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129-1136. (Pubitemid 120035062)
5. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934-937. (Pubitemid 19066153)
6. Peto M, Tolle-ErsüI, Kreysch HG, Klock G. Epidermal growth factor induction of human papillomavirus type 16 E6/E7 mRNA in tumour cells involves two AP-1 binding sites in the viral enhancer. J Gen Virol 1995; 76:1945-1958.
7. Narisawa-Saito M, Handa K, Yugawa T, Ohno S, Fujita M, Kiyono T. HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene 2007; 26:2988-2996. (Pubitemid 46733651)
8. Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, et al. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2011; 22:2166-2178.
9. Akerman GS, Tolleson WH, Brown KL, Zyzak LL, Mourateva E, Engin TS, et al. Human papillomavirus type 16 E6 and E7 cooperate to increase EGFR mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of human keratinocytes. Cancer Res 2001; 61:3837-3843. (Pubitemid 32695001)
10. Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1, 2 and PI3K/Akt. Cell Mol Life Sci 2006; 63: 930-938. (Pubitemid 43724080)
11. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA 2009; 106:3794-3799.
12. Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009; 15:7389-7397.
13. Johnson JA, Gangemi JD. Selective inhibition of human papillomavirusinduced cell proliferation by (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl]- cytosine. Antimicrob Agents Chemother 1999; 43:1198-1205. (Pubitemid 29214747)
14. Abdulkarim B, Sabri S, Deutsch E, Chagraoui E, Maggiorella L, Thierry J, et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002; 21: 2334-2346. (Pubitemid 34407293)
15. Sirianni N, Wang J, Ferris RL. Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005; 41:423-428. (Pubitemid 40387872)
16. Amine A, Vozenin-Brotons MC, Abdulkarim B, Violot D, Aubel C, Bourhis J. Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18 + cell lines. Radiat Res 2006; 166:600-610. (Pubitemid 44477713)
17. Amine A, Rivera S, Opolon P, Dekkai M, Biard DS, Bouamar H, et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One 2009; 4:e5018.
18. Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108:42-46.
19. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007; 106:513-520. (Pubitemid 47302461)
20. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005; 24:4433-4441. (Pubitemid 40961766)
21. Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 2011; 122:495-500.
22. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol 2011; 7:544.
23. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003; 100:7977-7982. (Pubitemid 36760080)
24. Vitale I, Galluzzi L, Vivet S, Lisa N, Dessen P, Senovilla L, et al. Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One 2007; 2:1337.
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-5868. (Pubitemid 28124064)
26. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003; 63:4347-4350. (Pubitemid 36951002)
27. Yang Y, Zhao X, Chen W, Gao Z, Liu A, Guo J, et al. Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice. Oncol Res 2010; 18:519-527.
28. Iida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 2011; 3:420-427.
29. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008; 49:1472-1478.
30. Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007; 4: 1239-1248. (Pubitemid 46711987)
31. Bandyopadhyay D, Mandal M, Adamn L. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273:1568-1573. (Pubitemid 28133681)
32. Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E, et al. In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother Oncol 2011; 101:147-151.
33. Farley J, Sill MW, Birrer M,Walker J, Schilder RJ, Thigpen JT, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group Study. Gynecol Oncol 2011; 121:303-308.
34. Cintorino M, Tripodi SA, Romagnoli R, Ietta F, Ricci MG, Paulesu L. Interferons and their receptors in human papillomavirus lesions of the uterine cervix. Eur J Gynaecol Oncol 2002; 23:145-150. (Pubitemid 34297119)
35. Johnson JA, Gangemi JD. Alpha interferon augments cidofovir's antiviral and antiproliferative activities. Antimicrob Agents Chemother 2003; 47:2022-2026. (Pubitemid 36637838)
36. Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, et al. Expression of IP-10 related to angiogenesis in uterine cervical cancers. Br J Cancer 2007; 96:1735-1739. (Pubitemid 46847211)
37. Akutagawa O, Nishi H, Kyo S, Terauchi F, Yamazawa K, Higuma C, et al. Early growth response-1 mediates downregulation of telomerase in cervical cancer. Cancer Sci 2008; 99:1401-1406. (Pubitemid 351761730)
38. Nishi H, Nishi KH, Johnson AC. Early growth response-1 gene mediates upregulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002; 62:827-834. (Pubitemid 34126960)
39. Kerpedjieva SS, Kim DS, Barbeau DJ, Tamama K. EGFR ligands drive mutlipotential stromal cells to produce multiple growth factors and cytokines via early growth response-1. Stem Cells Dev 2012; 21: 2541-2551.
40. Nutt JE, Foster PA, Mellon JK, Lunec J. EGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours. Br J Cancer 2007; 96:762-768. (Pubitemid 46376625)
41. Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, et al. EGFR mutation up-regulates EGR1 expression through the ERK pathway. Anticancer Res 2009; 29:1111-1118.
42. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65:3328-3335. (Pubitemid 40524617)
43. Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 2010; 29:2628-2637.